Clinical trial
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
NCT00301847 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00301847 |
|---|---|
| Title | Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain |
| Official title | A Phase 2 Study of Sorafenib (BAY 43-9006) in Metastatic Renal Cell Cancer to the Brain |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Metastatic Cancer |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 44 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2007 |
| First posted | Mar 13, 2006 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: